Wiener medizinische Wochenschrift
-
Wien Med Wochenschr · Jul 2011
Review Comparative Study[Actual state and perspectives of e-health in Austria and international--an overview].
eHealth will influence the development of the Austrian health and social care significantly. The main part will be the implementation of an electronic health record. There are many hospital and outpatient information systems already implemented and the challenge is to enable a patient-centered communication of all health care providers by defining technical standards and the organizational and legal framework. ⋯ Also, companies offering information systems have to improve the usability of their systems. One very important application is the filtering of relevant information according to a user profile and the optimal presentation in tables and graphs. The stepwise modular implementation and the use of international standards can be considered as a very positive approach to eHealth in Austria.
-
Wien Med Wochenschr · Apr 2011
ReviewThe role of milrinone in children with cardiovascular compromise: review of the literature.
Cardiovascular instability is a common complication in children after cardiac surgery and in various forms of shock. ⋯ There are a limited number of RCTs in children that suggest a beneficial effect of milrinone in the optimization of cardiovascular function after cardiac surgery and in septic shock.
-
Wien Med Wochenschr · Apr 2011
ReviewThe role of vasopressin and terlipressin in catecholamine-resistant shock and cardio-circulatory arrest in children: review of the literature.
Arginine-vasopressin (AVP) and terlipressin (TP) are used as rescue drugs for states of shock and cardio-circulatory failure. ⋯ No firm recommendations on the use of AVP/TP in children with severe forms of cardio-circulatory failure can be issued.
-
Wien Med Wochenschr · Feb 2011
Review Comparative StudyNew anticoagulants: pharmacology and clinical studies.
The marketing of new anticoagulant drugs has led us to review the development of rivaroxaban and apixaban (oral anti-Xa drugs) and dabigatran (an oral thrombin inhibitor). The results are different in terms of efficacy and tolerance. ⋯ Though the results are favourable for these orally active drugs in the orthopaedic setting, it is clear that only cardiological applications will give a final green light for these products. The future will be fascinating in this regard.